154 related articles for article (PubMed ID: 27487743)
1. High Prevalence of Acute Exacerbation of Interstitial Lung Disease in Japanese Patients with Systemic Sclerosis.
Tomiyama F; Watanabe R; Ishii T; Kamogawa Y; Fujita Y; Shirota Y; Sugimura K; Fujii H; Harigae H
Tohoku J Exp Med; 2016 Aug; 239(4):297-305. PubMed ID: 27487743
[TBL] [Abstract][Full Text] [Related]
2. Disease frequency, patient characteristics, comorbidity outcomes and immunosuppressive therapy in systemic sclerosis and systemic sclerosis-associated interstitial lung disease: a US cohort study.
Li Q; Wallace L; Patnaik P; Alves M; Gahlemann M; Kohlbrenner V; Raabe C; Wang JR; Garry EM
Rheumatology (Oxford); 2021 Apr; 60(4):1915-1925. PubMed ID: 33155024
[TBL] [Abstract][Full Text] [Related]
3. Healthcare Resource Utilization Among Patients in England with Systemic Sclerosis-Associated Interstitial Lung Disease: A Retrospective Database Analysis.
Gayle A; Schoof N; Alves M; Clarke D; Raabe C; Das P; Del Galdo F; Maher TM
Adv Ther; 2020 May; 37(5):2460-2476. PubMed ID: 32319038
[TBL] [Abstract][Full Text] [Related]
4. Characteristics and disease course of untreated patients with interstitial lung disease associated with systemic sclerosis in a real-life two-centre cohort.
Scheidegger M; Boubaya M; Garaiman A; Barua I; Becker M; Bjørkekjær HJ; Bruni C; Dobrota R; Fretheim H; Jordan S; Midtvedt O; Mihai C; Hoffmann-Vold AM; Distler O; Elhai M
RMD Open; 2024 Jan; 10(1):. PubMed ID: 38199606
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of anti-synthetase antibodies among systemic sclerosis patients.
Garra W; Levy Y
Eur J Intern Med; 2023 Nov; 117():98-102. PubMed ID: 37453844
[TBL] [Abstract][Full Text] [Related]
6. Baseline characteristics of systemic sclerosis patients with restrictive lung disease in a multi-center US-based longitudinal registry.
Castelino FV; VanBuren JM; Startup E; Assassi S; Bernstein EJ; Chung L; Correia C; Evnin LB; Frech TM; Gordon JK; Hant FN; Hummers LK; Khanna D; Sandorfi N; Shah AA; Shanmugam VK; Steen V
Int J Rheum Dis; 2022 Feb; 25(2):163-174. PubMed ID: 34841681
[TBL] [Abstract][Full Text] [Related]
7. Absence of interstitial lung disease at initial visit may predict a favorable outcome for Japanese patients with systemic sclerosis with anti-topoisomerase I antibody.
Hamaguchi Y; Yoshimura Y; Horii M; Fushida N; Kitano T; Sawada K; Oishi K; Maeda S; Watanabe S; Matsushita T
J Dermatol; 2024 Jan; 51(1):62-69. PubMed ID: 37864453
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of serum oncomarkers for patients hospitalized with acute exacerbation of interstitial lung disease.
Ba C; Jiang C; Wang H; Shi X; Jin J; Fang Q
Ther Adv Respir Dis; 2024; 18():17534666241250332. PubMed ID: 38757948
[TBL] [Abstract][Full Text] [Related]
9. [Characteristics of patients with systemic sclerosis who develop interstitial lung disease].
Fajardo-Hermosillo LD; Ocampo-Torres MC; Rodríguez-Silverio J
Rev Med Inst Mex Seguro Soc; 2023 Oct; 61(Suppl 3):S363-S371. PubMed ID: 37934671
[TBL] [Abstract][Full Text] [Related]
10. Comparison of nintedanib-induced gastrointestinal adverse events between patients with systemic sclerosis-associated interstitial lung disease and idiopathic interstitial pneumonias.
Imai M; Okabayashi H; Akaike K; Hamada S; Masunaga A; Ichiyasu H; Sakagami T
Respir Investig; 2024 May; 62(3):317-321. PubMed ID: 38395006
[TBL] [Abstract][Full Text] [Related]
11. Pulmonary manifestations and prognosis of a cohort of patients with interstitial lung disease and positive to anti-Th/To autoantibodies.
Mejía M; Ramos-Martínez E; Vázquez-Becerra LE; Fernández-Badillo D; Mateos-Toledo HN; Castillo J; Estrada A; Rojas-Serrano J
Med Clin (Barc); 2024 Apr; 162(8):378-384. PubMed ID: 38290874
[TBL] [Abstract][Full Text] [Related]
12. Economic Burden and Management of Systemic Sclerosis-Associated Interstitial Lung Disease in 8 European Countries: The BUILDup Delphi Consensus Study.
Davidsen JR; Miedema J; Wuyts W; Kilpeläinen M; Papiris S; Manali E; Robalo Cordeiro C; Morais A; Pérez M; Asijee G; Cendoya D; Soulard S
Adv Ther; 2021 Jan; 38(1):521-540. PubMed ID: 33156462
[TBL] [Abstract][Full Text] [Related]
13. Comorbidity and mortality in systemic sclerosis and matched controls: Impact of interstitial lung disease. A population based cohort study based on health registry data.
Knarborg M; Hyldgaard C; Bendstrup E; Davidsen JR; Løkke A; Shaker SB; Hilberg O
Chron Respir Dis; 2023; 20():14799731231195041. PubMed ID: 37596992
[TBL] [Abstract][Full Text] [Related]
14. Prediction of progressive fibrosing interstitial lung disease in patients with systemic sclerosis: insight from the CRDC cohort study.
Hui M; Duan X; Zhou J; Li M; Wang Q; Zhao J; Hou Y; Xu D; Zeng X
RMD Open; 2024 Mar; 10(1):. PubMed ID: 38519110
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of automated assessment of interstitial lung disease on CT in systemic sclerosis.
Le Gall A; Hoang-Thi TN; Porcher R; Dunogué B; Berezné A; Guillevin L; Le Guern V; Cohen P; Chaigne B; London J; Groh M; Paule R; Chassagnon G; Vakalopoulou M; Dinh-Xuan AT; Revel MP; Mouthon L; Régent A
Rheumatology (Oxford); 2024 Jan; 63(1):103-110. PubMed ID: 37074923
[TBL] [Abstract][Full Text] [Related]
16. Economic Burden of Illness Among Commercially Insured Patients with Systemic Sclerosis with Interstitial Lung Disease in the USA: A Claims Data Analysis.
Zhou Z; Fan Y; Thomason D; Tang W; Liu X; Zhou ZY; Macaulay D; Fischer A
Adv Ther; 2019 May; 36(5):1100-1113. PubMed ID: 30929184
[TBL] [Abstract][Full Text] [Related]
17. Contribution of Left Ventricular Diastolic Dysfunction to Survival and Breathlessness in Systemic Sclerosis-Associated Interstitial Lung Disease.
Fairley JL; Hansen D; Burns A; Prior D; La Gerche A; Morrisroe K; Stevens W; Nikpour M; Ross LJ
J Rheumatol; 2024 May; 51(5):495-504. PubMed ID: 38224991
[TBL] [Abstract][Full Text] [Related]
18. High serum C-X-C motif chemokine ligand 10 (CXCL10) levels may be associated with new onset interstitial lung disease in patients with systemic sclerosis: evidence from observational, clinical, transcriptomic and in vitro studies.
Al-Adwi Y; Atzeni IM; Doornbos-van der Meer B; van der Leij MJ; Varkevisser RDM; Kroesen BJ; Stel A; Timens W; Gan CT; van Goor H; Westra J; Mulder DJ
EBioMedicine; 2023 Dec; 98():104883. PubMed ID: 37995465
[TBL] [Abstract][Full Text] [Related]
19. Burden of Disease and Productivity Loss in the European Economic Area in Patients Affected by Fibrosing Interstitial Lung Disease.
Løkke A; Castello L; Pinheiro Martins P; Soulard S; Hilberg O
Adv Ther; 2023 Dec; 40(12):5502-5518. PubMed ID: 37837527
[TBL] [Abstract][Full Text] [Related]
20. Clinical characteristics and disease course before and after SARS-CoV-2 infection in a large cohort of systemic sclerosis patients.
Güler AA; Özçimen B; Aydoğdu MS; Sari A; Numune A; Ersan NT; Çolak S; Karadeniz H; Vasi İ; Küçük H; Yalçinkaya Y; Erden A; Kayaalp M; Öztürk MA; Göker B; Omma A; Yilmaz S; Koca SS; Inanç M; Akdoğan A; Tufan A
Turk J Med Sci; 2024; 54(1):76-85. PubMed ID: 38812619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
